Altamira Therapeutics Ltd. (NASDAQ:CYTO) went up by 13.79% from its latest closing price compared to the recent 1-year high of $6.60. The company’s stock price has collected -7.51% of loss in the last five trading sessions. Press Release reported 2 hours ago that Altamira Therapeutics Receives FDA Acceptance for Bentrio 510(k) Application
Is It Worth Investing in Altamira Therapeutics Ltd. (NASDAQ :CYTO) Right Now?
Plus, the 36-month beta value for CYTO is at 1.30. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Altamira Therapeutics Ltd. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $14.30. Today, the average trading volume of CYTO was 473.60K shares.
CYTO’s Market Performance
CYTO stocks went down by -7.51% for the week, with a monthly drop of -31.03% and a quarterly performance of -47.02%, while its annual performance rate touched 55.34%. The volatility ratio for the week stands at 9.48% while the volatility levels for the past 30 days are set at 8.04% for Altamira Therapeutics Ltd.. The simple moving average for the period of the last 20 days is -9.24% for CYTO stocks with a simple moving average of -41.72% for the last 200 days.
CYTO Trading at -26.46% from the 50-Day Moving Average
After a stumble in the market that brought CYTO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.41% of loss for the given period.
Volatility was left at 8.04%, however, over the last 30 days, the volatility rate increased by 9.48%, as shares sank -15.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.81% lower at present.
During the last 5 trading sessions, CYTO rose by +3.80%, which changed the moving average for the period of 200-days by -29.26% in comparison to the 20-day moving average, which settled at $1.9890. In addition, Altamira Therapeutics Ltd. saw -38.93% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CYTO
The total capital return value is set at -45.08, while invested capital returns managed to touch -69.32. Equity return is now at value -90.50, with -66.00 for asset returns.
Based on Altamira Therapeutics Ltd. (CYTO), the company’s capital structure generated 3.12 points at debt to equity in total, while total debt to capital is 3.03.
The liquidity ratio also appears to be rather interesting for investors as it stands at 3.83.